173 related articles for article (PubMed ID: 31116603)
1. Intravenous versus subcutaneous trastuzumab: an economic and patient perspective.
Mitchell H; Morrissey D
Br J Nurs; 2019 May; 28(10):S15-S20. PubMed ID: 31116603
[TBL] [Abstract][Full Text] [Related]
2. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
[TBL] [Abstract][Full Text] [Related]
3. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
[TBL] [Abstract][Full Text] [Related]
4. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
5. Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries.
Inotai A; Ágh T; Karpenko AW; Zemplényi A; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):105-113. PubMed ID: 30488730
[TBL] [Abstract][Full Text] [Related]
6. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer.
Olsen J; Jensen KF; Olesen DS; Knoop A
J Comp Eff Res; 2018 May; 7(5):411-419. PubMed ID: 29199854
[TBL] [Abstract][Full Text] [Related]
7. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
[TBL] [Abstract][Full Text] [Related]
8. Cost minimization analysis of subcutaneous trastuzumab versus intravenous biosimilar trastuzumab: policy recommendations for breast cancer treatment in Malaysia.
Heng JE; Raman S; Wong ZY; Beh VJN
Daru; 2024 Jun; 32(1):67-76. PubMed ID: 37903943
[TBL] [Abstract][Full Text] [Related]
9. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
Waller CF; Möbius J; Fuentes-Alburo A
Br J Cancer; 2021 Apr; 124(8):1346-1352. PubMed ID: 33589773
[TBL] [Abstract][Full Text] [Related]
10. Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
Elsamany S; Elsisi GH; Hassanin F; Jafal M
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):511-518. PubMed ID: 33275459
[No Abstract] [Full Text] [Related]
11. Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden.
Valachis A; Sundqvist M; Carlsson L; Li B; Chiesa F; Uhde M; Sanglier T
Future Oncol; 2019 Aug; 15(23):2733-2741. PubMed ID: 31306041
[No Abstract] [Full Text] [Related]
12. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
[TBL] [Abstract][Full Text] [Related]
13. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
15. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
[No Abstract] [Full Text] [Related]
16. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
Pivot X; Spano JP; Espie M; Cottu P; Jouannaud C; Pottier V; Moreau L; Extra JM; Lortholary A; Rivera P; Spaeth D; Attar-Rabia H; Benkanoun C; Dima-Martinez L; Esposito N; Gligorov J
Eur J Cancer; 2017 Sep; 82():230-236. PubMed ID: 28648618
[TBL] [Abstract][Full Text] [Related]
17. [Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)].
Favier M; Le Goc-Sager F; Vincent-Cantini I; Launay V; Giroux EA; Lièvremont K; Bonnet I; Barbe C; Duval E; Loric N; Delbaldo C
Bull Cancer; 2018 Oct; 105(10):862-872. PubMed ID: 30244982
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Trastuzumab After Subcutaneous and Intravenous Administration in Obese Patients.
González García J; Gutiérrez Nicolás F; Ramos Díaz R; Nazco Casariego GJ; Viña Romero MM; Llabres Martinez M; Llanos Muñoz M; Batista López JN; Jiménez Sosa A; Ceballos Lenza I; Cruz Jurado J
Ann Pharmacother; 2020 Aug; 54(8):775-779. PubMed ID: 31971005
[No Abstract] [Full Text] [Related]
20. Subcutaneous auto-administration of trastuzumab following therapeutic education: A case report.
Deppenweiler M; Debled M; Robquin JL; Lortal-Canguilhem B
J Oncol Pharm Pract; 2019 Sep; 25(6):1523-1525. PubMed ID: 30126339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
